Ra Pharmaceuticals (NASDAQ:RARX) will host a conference call on Tuesday, June 27, at 8:00 am ET to discuss preliminary data from its Phase 2 clinical trial assessing lead candidate RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Patient dosing started in late April.
RA101495 is a subcutaneously administered inhibitor of complement component 5 (C5).
Previously: Mid-stage study underway assessing Ra Pharma's RA101495 for PNH (April 26)
Subscribe for full text news in your inbox